Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
Non-Hodgkin's Lymphoma
DRUG: Ofatumumab combined with SB-485232
To evaluate the the number of subjects with adverse events who receive SB-485232 when given in combination with ofatumumab, Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 which uses a scale of 1 (mild) to 5 (caused death)., 8 weeks
To evaluate the biologic effects of SB-485232 given in combination with ofatumumab, Biologic effects will be assessed by flow cytometric analysis of PBMCs and ELISA tests to measure plasma cytokines and chemokines., 8 weeks
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.